Radical Biotechnology Pty Ltd

Novel Cardiovascular Disease Therapy

Radical Biotechnology aims to develop the first class of therapeutics that actually target the underlying cause of cardiovascular disease, rather than the symptoms, thus inhibiting and possibly reversing its progression.

The company is currently completing a series of key in vivo trials in animal models of high blood pressure, heart disease and stroke, using novel lead molecules developed by the company.

Uniseed Investment Committee Project Manager: Grant Morley